Switch from biologic to biosimilar drug requires monitoring, patient-informed discussion
When it comes to switching from a biologic to a biosimilar drug, patient choice and engagement is extremely important, according to Durhane Wong-Rieger, president and chief executive…
- By: Cassandra Williamson-Hopp
- November 8, 2019 November 12, 2020
- 08:46